Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants

Abstract

These findings suggest that dosage adjustment to diminish side effects does not compromise risperidone response and that disorganized patients and perhaps patients with longer illness duration are prone to receive larger doses.

Sarcosine or D-Serine Add-on Treatment for Acute Exacerbation of Schizophrenia

“…After hospital admission, the duration of the placebo lead-in period and the risperidone doses during the trial were also similar among the groups (Table 1). The symptom severity of the patients was similar to that in the clinical trials 25,26 of schizophrenia with acute exacerbation.…”

“…25,26 For acutely exacerbated individuals, the mean end-point dosages in most studies [27][28][29][30][31] were 8 to 12 mg/d; another study 32 used a fixed dose of 6 mg/d. However, in previous studies 25,26 in a similar population we found that the dosing strategy to minimize adverse effects can still yield favorable efficacy. Therefore, we applied the same dosing strategy to obtain the optimal response to risperidone treatment in this study.…”

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting

“…Risperidone has been known to be effective to 60-80% of acutely exacerbated schizophrenia patients (Lane et al, 2000(Lane et al, , 2004. In this study, 17 patients (17%) showed no change or worsening of symptoms (i.e., they scored 4 or more on the CGI-I) after 4 weeks of risperidone treatment, and these patients were thus categorized as nonresponders.…”

A Comparative Efficacy and Safety Study of Long-Acting Risperidone Injection and Risperidone Oral Tablets Among Hospitalized Patients: 12-Week Randomized, Single-Blind Study

“…According to the consensus guideline for switching from oral antipsychotics to RLAI [13], the original oral risperidone dose was maintained for the first 3 weeks, after which time it was either stopped or tapered off within 3 days because of the time required to achieve therapeutic serum levels of RLAI. The consensus guideline also suggested that 25 mg dose of RLAI is adequate for most patients [13], and the average oral dose of risperidone for schizophrenic patients in Taiwan was less than 4 mg/day [15,19]. Therefore, we defined the dose switching equivalency as 25 mg RLAI for an original risperidone dose less or equal to 4 mg/day, 37.5 mg RLAI for an original risperidone dose of more than 4 and less or equal 6 mg/day, and 50 mg RLAI for an original risperidone dose of more than 6 mg/day.…”